FDA Sets July PCAC Meeting to Review Seven Peptide Therapies

The Food and Drug Administration has scheduled a July 2026 meeting of its Pharmacy Compounding Advisory Committee (PCAC) to review seven peptide therapies, including BPC-157, TB-500, and five other compounds that have been at the center of a growing debate over peptide regulation, the FDA confirmed in a Federal Register notice this week.

The meeting marks the next major milestone in a regulatory saga that began in April 2025, when the FDA under the Biden administration added nearly 20 peptides to the “demonstrably difficult to compound” list under Section 503A of the Food, Drug, and Cosmetic Act. That designation effectively barred compounding pharmacies from producing the substances without an FDA-approved equivalent on the market.

What the July PCAC meeting will consider

The PCAC — an advisory panel composed of pharmacy experts, clinicians, and consumer representatives — will evaluate whether seven specific peptides meet the statutory criteria for bulk compounding. The committee’s recommendation, while non-binding, historically carries significant weight with FDA decision-makers.

The seven peptides under review include some of the most widely used in the wellness space:

• BPC-157 — marketed for injury recovery and gastrointestinal health
• TB-500 — promoted for tissue repair and inflammation modulation
• KPV — a tripeptide studied for its anti-inflammatory properties
• MOTS-c — a mitochondrial peptide associated with metabolic regulation
• GHK-Cu — a copper peptide used in wound healing and dermatology
• Semax — a synthetic peptide investigated for cognitive effects
• Epitalon — studied in aging research

Melanotan II, another of the 12 reclassified peptides, is notably absent from the July PCAC agenda despite growing mainstream attention following the “Barbie Drug” tanning coverage in May 2026.

Health and Human Services Secretary Robert F. Kennedy Jr. has been a vocal advocate for broader peptide access, publicly discussing his personal use of peptide therapies and directing the FDA to re-examine the 2025 restrictions. In an April 15 directive, Kennedy called the previous administration’s approach “overly restrictive” and ordered the agency to develop a path forward.

What changes between now and July

The FDA has indicated it will remove the seven peptides from the Category 2 (restricted) list in the interim, before the PCAC meets. This would effectively allow compounding pharmacies to begin producing them — though the FDA cautions that these products have not undergone the standard premarket safety and efficacy review required of new drugs.

Dr. Peter Lurie, a former FDA associate commissioner who now leads the Center for Science in the Public Interest, told the Associated Press that the accelerated approach poses a “profound threat” to the FDA’s drug approval framework.

“I don’t see why one would take the path of a proper drug approval if there is now this less rigorous, alternative path to market,” Lurie said.

The PCAC currently has several vacancies that Kennedy could fill before the July meeting, a factor that could influence the committee’s composition and recommendations.

What this means for patients and providers

For patients currently using compounded peptide therapies, the July PCAC outcome could determine whether these substances remain legally accessible through licensed pharmacies. Providers should note that:

• The FDA’s interim removal from the Category 2 list does not constitute FDA approval
• Compounded peptides produced under 503A are not subject to the same quality controls as FDA-approved drugs
• Patients should discuss any peptide therapy with a licensed healthcare provider

PeptidesBeat will provide full coverage of the PCAC meeting, including pre-meeting briefing documents, live analysis, and post-decision regulatory guidance. The growing mainstream media scrutiny of peptides — covered in our analysis of media coverage — adds a public-opinion dimension to the regulatory proceedings.

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.